# Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death

**Authors:** Scott C. Schuyler, Rythm Gupta, Tran Thi Bao Nguyen, Cheng-Ye Weng, Hsin-Yu Chen

PMC · DOI: 10.3390/molecules30040895 · Molecules · 2025-02-14

## TL;DR

This study identifies small molecules that enhance paclitaxel's effect on breast cancer cells by targeting APC1, a key cell cycle regulator.

## Contribution

The study introduces new small molecules that synergize with paclitaxel to increase breast cancer cell death.

## Key findings

- Two compounds with a 2-(trifluoromethyl)quinazolin-4-amine structure enhanced paclitaxel-induced cell death in breast cancer cells.
- The compounds were identified via in silico docking and validated in cellulo.
- These molecules will guide further optimization and in silico screens for more potent anti-cancer agents.

## Abstract

Delaying mitotic cell cycle progression has been proposed as a strategy to potentiate the effects of anti-mitotic anti-cancer drugs that induce multipolar mitotic spindles. Toward this end, we have performed an in silico docking screen targeting anaphase-promoting complex/cyclosome subunit 1 (APC1) at a conserved 10-amino acid surface site that was modeled to interact via a single hydrogen bond with the essential mitotic anaphase-promoting complex/cyclosome (APC/C) co-factor cell division cycle 20 (CDC20). Five molecules were identified after screening 15,000 small molecules. As a secondary in cellulo bioactivity screening, MDA-MB-231 genomically unstable aneuploid breast cancer cells were exposed to each compound in the absence and presence of 10 nM paclitaxel or 1 nM eribulin, the likely clinically relevant doses of these drugs in these cells. Two of the five compounds, which share a common 2-(trifluoromethyl)quinazolin-4-amine chemical structure, induced elevated levels of cell death in combination with paclitaxel, as observed by fluorescence-activated cell sorting (FACS). These two compounds will now serve as a starting point for further optimization and target validation experiments and for additional in silico screens in search of other chemically related small molecules that display more potent but specific anti-cancer cell effects.

## Linked entities

- **Genes:** SLC25A24 (solute carrier family 25 member 24) [NCBI Gene 29957], CDC20 (cell division cycle 20) [NCBI Gene 991]
- **Chemicals:** paclitaxel (PubChem CID 36314), eribulin (PubChem CID 11354606), 2-(trifluoromethyl)quinazolin-4-amine (PubChem CID 20646240)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** CDC20 (cell division cycle 20) [NCBI Gene 991] {aka CDC20A, OOMD14, OZEMA14, bA276H19.3, p55CDC}, ANAPC1 (anaphase promoting complex subunit 1) [NCBI Gene 64682] {aka APC1, MCPR, TSG24}
- **Diseases:** Breast Cancer (MESH:D001943), cancer (MESH:D009369)
- **Chemicals:** Paclitaxel (MESH:D017239), 2-(trifluoromethyl)quinazolin-4-amine (-), eribulin (MESH:C490954)
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11857951/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11857951/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC11857951/full.md

---
Source: https://tomesphere.com/paper/PMC11857951